MYX 2.76% $4.22 mayne pharma group limited

Ann: Preliminary Final Report, page-2

  1. 296 Posts.
    lightbulb Created with Sketch. 2
    Sounds solid to me!

    • Revenue of $572.6m, an increase of 114% on FY16
    • Underlying EBITDA of $206.5m, up 133% on FY16
    • Reported EBITDA of $204.0m, up 165% on FY16
    • Reported net profit after tax was $88.6m, up 137% on FY16
    • Basic earnings per share of 6.2c, up 30% on FY16
    • Positive operating cash flow in 2H17 of $51.9m
    Last edited by EckQuity: 25/08/17
 
watchlist Created with Sketch. Add MYX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.